Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL

Clinical trial NCT03795571 · UNKNOWN

Trial details

NCT number: NCT03795571
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Diffuse Large B-cell Lymphoma Recurrent Diffuse Large B Cell Lymphoma Refractory

Start date: 2019-01-01
Primary completion: 2019-12-31
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.